United Kingdom
PolyPhotonix, founded in 2009 in the North East of England, is a biophotonic research and development company focused on designing, developing, and manufacturing non-invasive photonic based medical devices. The company's slogan "Saving sight with light" encapsulates its mission to address serious complications of diabetes such as Diabetic Retinopathy and Diabetic Macular Oedema, which are the principal causes of blindness among people of working age in the UK. PolyPhotonix has successfully brought its first medical device, the Noctura 400 Sleep Mask, through clinical trials to market.
This transformational treatment for eye diseases showcases the potential of light therapy in the healthcare industry. Recently, the company received a Debt Financing investment on 16 January 2024 from NPIF - FW Capital Debt Finance. This investment signifies external validation and support for PolyPhotonix's innovative approach to healthcare technology. For more details, visit their product website www.noctura.com. Contact them at +44 (0) 1740 625 555 or [email protected].
PolyPhotonix's focus on addressing prevalent medical issues with cutting-edge technology positions it as a promising investment opportunity. The company's commitment to leveraging light-based therapy for healthcare signifies its potential for growth and impact within the industry. As the company continues to develop innovative solutions, it presents an exciting prospect for investors seeking to support advancements in medical technology.
